Tigenix Sa (TGXSF) 0.7500 $TGXSF
TiGenix: TiGenix starts Cx601 Marketing Authorisation Application process
GlobeNewswire - Thu Jun 11, 12:06AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has submitted to the European Medicines Agency (EMA) a letter of intent to file, and a request for the assignment of Rapporteur/Co-Rapporteur, for the Marketing Authorisation Application (MAA) of Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix: Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial
GlobeNewswire - Thu May 28, 12:07AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the results of its Phase I sepsis challenge trial of Cx611 confirm safety and tolerability.
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 5.22 (+0.14), BAX: 37.61 (+0.59), ACH: 10.36 (+0.79)
TiGenix: Notice in relation to the convertible bonds due 2018
GlobeNewswire - Thu May 14, 4:22AM CDT
THIS NOTICE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
TiGenix's Phase 3 Trial Of Allogeneic Stem Cells Is Likely To Succeed
Logribel Biostocks - at Seeking Alpha - Wed May 13, 8:44AM CDT
PFE: 34.36 (+0.50), OSIR: 19.31 (+0.65), GSK: 42.45 (+0.65), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas
GlobeNewswire - Wed Apr 08, 12:40AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent 8,999,709 relating to the use of an adipose-derived stromal cell population in the treatment of fistula. The patent, entitled "Use of adipose tissue-derived stromal stem cells in treating fistula", expires in 2030 and provides coverage for the company's lead development product, Cx601, in the key US market.
Putting A Tiger In Your Portfolio: Tigenix Has Upside Potential
Capital Screen - at Seeking Alpha - Tue Mar 24, 7:16AM CDT
TiGenix: CONVENING NOTICE TO THE ANNUAL AND THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 20 APRIL 2015
GlobeNewswire - Fri Mar 20, 1:04AM CDT
The board of directors of TiGenix NV (the "Company"
is pleased to invite you to the annual and the extraordinary shareholders' meeting of TiGenix NV that will be held at the registered office of TiGenix NV (Romeinse straat 12 box 2, 3001 Leuven) on 20 April 2015 at 10:00 a.m., in the presence of a notary, with the agenda and proposed resolutions set out below.
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 31.28 (+0.47), NVS: 103.22 (+3.20)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 232.32 (+8.93), SLXP: 172.96 (+0.15), ICPT: 247.71 (+4.45), SPPI: 7.08 (+0.05), EXAS: 27.35 (+0.02)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.71 (-0.03), OCAT: 5.22 (+0.14), PSTI: 2.40 (+0.03)
TiGenix: TiGenix participates in key conferences in the first half of 2015
GlobeNewswire - Mon Feb 02, 12:06AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.
TiGenix: European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions
GlobeNewswire - Thu Jan 22, 12:04AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled " Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue ". The claims of the granted patent cover both a specified population of expanded adipose-derived multipotent cells and their therapeutic uses, as well as pharmaceutical compositions of such cells.
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.36 (+0.50), OSIR: 19.31 (+0.65), GSK: 42.45 (+0.65), ATHX: 1.14 (-0.01)
TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment
GlobeNewswire - Mon Dec 22, 12:09AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has submitted to the Food and Drug Administration (FDA) the required documentation for a Special Protocol Assessment (SPA) of its pivotal Phase III trial design for Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease in the United States. Agreement with the FDA on the SPA will ensure that the trial design is aligned with the FDA's requirements for the future approval of Cx601.
TiGenix: TiGenix to participate or present at key conferences in the second half of 2014
GlobeNewswire - Mon Sep 15, 2:03AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.
European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601
GlobeNewswire - Mon Sep 08, 12:04AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation
Thomson Reuters ONE - Tue Sep 02, 10:29AM CDT
Leuven (BELGIUM) - 1 September, 2014 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company's Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.
TiGenix: TiGenix starts Cx601 Marketing Authorisation Application process
GlobeNewswire - Thu Jun 11, 12:06AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has submitted to the European Medicines Agency (EMA) a letter of intent to file, and a request for the assignment of Rapporteur/Co-Rapporteur, for the Marketing Authorisation Application (MAA) of Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix: Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial
GlobeNewswire - Thu May 28, 12:07AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the results of its Phase I sepsis challenge trial of Cx611 confirm safety and tolerability.
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 5.22 (+0.14), BAX: 37.61 (+0.59), ACH: 10.36 (+0.79)
TiGenix: Notice in relation to the convertible bonds due 2018
GlobeNewswire - Thu May 14, 4:22AM CDT
THIS NOTICE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL
TiGenix's Phase 3 Trial Of Allogeneic Stem Cells Is Likely To Succeed
Logribel Biostocks - at Seeking Alpha - Wed May 13, 8:44AM CDT
PFE: 34.36 (+0.50), OSIR: 19.31 (+0.65), GSK: 42.45 (+0.65), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
TiGenix: USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas
GlobeNewswire - Wed Apr 08, 12:40AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent 8,999,709 relating to the use of an adipose-derived stromal cell population in the treatment of fistula. The patent, entitled "Use of adipose tissue-derived stromal stem cells in treating fistula", expires in 2030 and provides coverage for the company's lead development product, Cx601, in the key US market.
Putting A Tiger In Your Portfolio: Tigenix Has Upside Potential
Capital Screen - at Seeking Alpha - Tue Mar 24, 7:16AM CDT
TiGenix: CONVENING NOTICE TO THE ANNUAL AND THE EXTRAORDINARY SHAREHOLDERS' MEETING TO BE HELD ON 20 APRIL 2015
GlobeNewswire - Fri Mar 20, 1:04AM CDT
The board of directors of TiGenix NV (the "Company"
is pleased to invite you to the annual and the extraordinary shareholders' meeting of TiGenix NV that will be held at the registered office of TiGenix NV (Romeinse straat 12 box 2, 3001 Leuven) on 20 April 2015 at 10:00 a.m., in the presence of a notary, with the agenda and proposed resolutions set out below. TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 31.28 (+0.47), NVS: 103.22 (+3.20)
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 232.32 (+8.93), SLXP: 172.96 (+0.15), ICPT: 247.71 (+4.45), SPPI: 7.08 (+0.05), EXAS: 27.35 (+0.02)
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.71 (-0.03), OCAT: 5.22 (+0.14), PSTI: 2.40 (+0.03)
TiGenix: TiGenix participates in key conferences in the first half of 2015
GlobeNewswire - Mon Feb 02, 12:06AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.
TiGenix: European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions
GlobeNewswire - Thu Jan 22, 12:04AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition. The patent is entitled " Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue ". The claims of the granted patent cover both a specified population of expanded adipose-derived multipotent cells and their therapeutic uses, as well as pharmaceutical compositions of such cells.
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.36 (+0.50), OSIR: 19.31 (+0.65), GSK: 42.45 (+0.65), ATHX: 1.14 (-0.01)
TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment
GlobeNewswire - Mon Dec 22, 12:09AM CST
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has submitted to the Food and Drug Administration (FDA) the required documentation for a Special Protocol Assessment (SPA) of its pivotal Phase III trial design for Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease in the United States. Agreement with the FDA on the SPA will ensure that the trial design is aligned with the FDA's requirements for the future approval of Cx601.
TiGenix: TiGenix to participate or present at key conferences in the second half of 2014
GlobeNewswire - Mon Sep 15, 2:03AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.
European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601
GlobeNewswire - Mon Sep 08, 12:04AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation
Thomson Reuters ONE - Tue Sep 02, 10:29AM CDT
Leuven (BELGIUM) - 1 September, 2014 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company's Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.
